Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Naval Daver, MD, Provides Perspective on Updates in Acute Myeloid Leukemia

January 12, 2020
By Naval Daver, MD
News
Article
Conference|ASH Annual Meeting & Exposition: Leukemia

Naval Daver, MD, explains the progress made on 3 abstracts he’s involved with regarding acute myeloid leukemia (AML) at the ASH Annual Meeting and Exposition.

Naval Daver, MD, from The University of Texas MD Anderson Cancer Center in Houston, discussed a number of studies regarding acute myeloid leukemia (AML) treatments presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held December 7-10, in Orlando, Florida.

Transcription:

On a phase II study with azacytidine (Vidaza) and nivolumab (Opdivo)

So, the study has been completed and has 70 patients on it in the relapsed setting with azacytidine and nivolumab. The overall response rate we see is about 35% for (complete response) and marrow clearance. We see an additional 10%-11% of patients who have very interesting and unique stable disease, where the disease never achieved remission, but they had more than 6 months with improvement in transfusion, outpatient, improved quality of life, which of course is very well known to be occurring with immune checkpoint therapy in solid tumors. So, we think in general about 40%-45% of patients had clinical benefit beyond what we would see in general with AML therapies.

On a phase I study of milademetan in combination with quizartinib

That was the preclinical rationale. We in fact saw mouse survivals that were maintained at more than 100 days, which is almost unheard of in acute myeloid leukemia relapse studies. So, we think that the preclinical synergy could be very, very, very exciting, and that has led to this phase I study.

On a phase Ib trial of venetoclax (Venclexta) in combination with idasanutlin

This data was actually published in a very high impact journal Cancer Cell. What we found was that, when we inhibited MDM2, this seemed to synergize nicely with venetoclax BCL2 inhibition by 2 independent pathways. One was that MDM2 inhibition inhibited the MAP kinase pathway, and this promoted the degradation of MCL1. MCL1 is the most important resistance protein to venetoclax so this was nice, and it would allow venetoclax to work longer or have responses in those who would have otherwise escaped. Also, the inhibition of MDM2 up regulated independently pro apoptotic pathways BAX, BAD, BIM, and these further stabilize MCL1.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML

Gina Mauro
June 15th 2025
Article

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.


Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Ariana Pelosci
June 14th 2025
Article

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.

Related Content

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.


Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.


Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.


Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.


Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML

Gina Mauro
June 15th 2025
Article

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.


Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Ariana Pelosci
June 14th 2025
Article

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.